Manandhar, N.R., Kayashta, G.K. and Acharya, P.K. 2018. Dasatinib tyrosine kinase inhibitor as second and third line therapy in chronic myeloid leukemia: outcome of a Nepalese study. Journal of Patan Academy of Health Sciences. 5, 1 (Jun. 2018), 47–56. DOI:https://doi.org/10.3126/jpahs.v5i1.24042.